Sight Sciences reports preliminary Q4 revenue $20.3M-$20.4M, consensus $20.17M

“We are pleased with our progress in the fourth quarter, including approximately 7% revenue growth compared to the prior year period, strong cash management, significant Dry Eye reimbursement milestones, and continued Surgical Glaucoma momentum,” said Paul Badawi, Co-Founder and CEO of Sight Sciences (SGHT). “Key Dry Eye achievements include the establishment of two Medicare Administrative Contractor fee schedules and positive early validation of our reimbursed interventional Dry Eye business model. As we continue building a leading interventional eye care company, we remain confident in our growth outlook, operational discipline, and path toward cash flow breakeven without requiring additional equity capital.”